Clinical Trial of Rybelsus (Semaglutide) Among Adults With Alcohol Use Disorder (AUD)
NCT05892432 on ClinicalTrials.gov · last registry update 2025-12-26
A small phase 2 — 50 participants, against a typical 110. The sponsor logged completion for 4 November 2025. Primary outcome, as filed: Change in Cue Craving Visual Analog Score. semaglutide is approved in the US, but not for alcohol use disorder — a registration here is not an approval, and most drugs tested in a new condition never get one for it.
- Status
- COMPLETED
- Phase
- P2
- Drug
- semaglutideOzempic, Rybelsus, Wegovy
- Sponsor type
- Other
- Enrollment
- 50
- Started
- 2024-01-11
- Primary completion
- 2025-11-04 actual
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Change in Cue Craving Visual Analog Score
Conditions studied
Alcohol Use Disorder
Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.